Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 5/20 | 0.49 |
| ▸ | ESR1 | P03372 | 1/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 5/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.41 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.41 |
| ▸ | PPARA | Q07869 | 4/20 | 0.41 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.39 |
| ▸ | ADRB3 | P13945 | 3/20 | 0.39 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4830943 | 1.00 | PPARG (0.49) | PPARGESR1ESR2MAPTPKM | |
| SCHEMBL4833520 | 0.80 | MAOB (0.49) | PPARGPPARAMAPK1RAB9A | |
| SCHEMBL4833526 | 0.80 | MAOB (0.49) | PPARGPPARAMAPK1RAB9A | |
| SCHEMBL10907007 | 0.75 | PTPN11 (0.59) | ESR1ESR2MAPTSMN1; SMN2PTPN11 | |
| SCHEMBL6272441 | 0.74 | PPARG (0.65) | PPARGPPARAS1PR1MAPK1RAB9A | |
| SCHEMBL6272436 | 0.74 | PPARG (0.65) | PPARGPPARAS1PR1MAPK1RAB9A | |
| SCHEMBL4831156 | 0.73 | MAPT (0.46) | ESR1ESR2MAPTTDP1KDM4E | |
| SCHEMBL4831149 | 0.73 | MAPT (0.46) | ESR1ESR2MAPTTDP1KDM4E | |
| SCHEMBL9785919 | 0.72 | ESR1 (0.71) | ESR1ESR2MAPTPKMTDP1 | |
| SCHEMBL6933865 | 0.71 | PPARG (0.54) | PPARGPPARAS1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7420083-B2 | Substituted aryloximes | WYETH (US) | 2008-09-02 | — | — | US | claimed |
| EP-1663189-A1 | 4-(PHENYL-ETHYLIDENEAMINOXY-PROPOXY)-PHENYL-ACETIC ACID DERIVATIVES AND RELATED COMPOUNDS AS PAI-1 INHIBITORS FOR THE TREATMENT OF IMPAIREMENT OF THE FIBRINOLYTIC SYSTEM AND OF THROMBISIS | Wyeth (US) | 2006-06-07 | — | — | EP | claimed |
| WO-2005030193-A1 | 4-(PHENYL-ETHYLIDENEAMINOXY-PROPOXY) -PHENYL-ACETIC ACID DERIVATIVES AND RELATED COMPOUNDS AS PAI-1 INHIBITORS FOR THE TREATMENT OF IMPAIRMENT OF THE FIBRINOLYTIC SYSTEM AND OF THROMBOSIS | WYETH (US) | 2005-04-07 | — | — | WO | claimed |
| US-20050070584-A1 | Substituted aryloximes | WYETH (US) | 2005-03-31 | — | — | US | claimed |
| US-20080293790-A1 | SUBSTITUTED ARYL OXIMES | WYETH (US) | 2008-11-27 | — | — | US | disclosed |
| US-7420083-B2 | Substituted aryloximes | WYETH (US) | 2008-09-02 | — | — | US | disclosed |
| EP-1663189-A1 | 4-(PHENYL-ETHYLIDENEAMINOXY-PROPOXY)-PHENYL-ACETIC ACID DERIVATIVES AND RELATED COMPOUNDS AS PAI-1 INHIBITORS FOR THE TREATMENT OF IMPAIREMENT OF THE FIBRINOLYTIC SYSTEM AND OF THROMBISIS | Wyeth (US) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005030193-A1 | 4-(PHENYL-ETHYLIDENEAMINOXY-PROPOXY) -PHENYL-ACETIC ACID DERIVATIVES AND RELATED COMPOUNDS AS PAI-1 INHIBITORS FOR THE TREATMENT OF IMPAIRMENT OF THE FIBRINOLYTIC SYSTEM AND OF THROMBOSIS | WYETH (US) | 2005-04-07 | — | — | WO | disclosed |
| US-20050070584-A1 | Substituted aryloximes | WYETH (US) | 2005-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070584-A1 | Substituted aryloximes | AHR, NQO1, AOX1 | PPARG 610/4885ESR1 827/4885ESR2 460/4885 |
| US-20080293790-A1 | SUBSTITUTED ARYL OXIMES | HCCS, AOX1, TET2 | PPARG 631/4885ESR1 860/4885ESR2 464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.